ライフサイエンスコーパス: parathyroid hormone

1 5-hydroxyvitamin D, phosphorus, calcium, and parathyroid hormone).

2 ts increase is associated with a decrease in parathyroid hormone.

3 (receptor activator of NFkappaB ligand) and parathyroid hormone.

4 There was no effect modification by parathyroid hormone.

5 nd action of fibroblast growth factor 23 and parathyroid hormone.

6 blood pressure or arterial pressure and with parathyroid hormone.

7 clic AMP responded to external cues, such as parathyroid hormone.

8 hyroid tissue causing excessive secretion of parathyroid hormone.

9 ized by hypercalcemia and elevated levels of parathyroid hormone.

10 er characterized by autonomous production of parathyroid hormone.

11 or inappropriately normal concentrations of parathyroid hormone.

12 The parathyroid hormone 1 receptor (PTHR) is central to the

13 In another study, we showed that parathyroid hormone 1-34 and anti-sclerostin antibody at

14 tolerability of once-daily recombinant human parathyroid hormone 1-84 (rhPTH[1-84]) in adults with hy

15 Studies by Sato et al. reveal a role for parathyroid hormone 2 receptor (PTH2R) in extracellular

16 f 39 residues (TIP39), via its receptor, the parathyroid hormone 2 receptor (PTH2R), modulates fear m

17 Small interfering RNA-mediated silencing of parathyroid hormone 2 receptor (PTH2R), the receptor for

18 hese areas are enriched in its receptor, the parathyroid hormone 2 receptor (PTH2R).

19 racteristics, dietary intakes, fasting serum parathyroid hormone, 25-hydroxyvitamin D [25(OH)D], and

20 Parathyroid hormone, 25-hydroxyvitamin D, liver function

21 ge mean+/-SD single-pass renal extraction of parathyroid hormone (44.2%+/-10.3%) that exceeded the ex

22 Parathyroid hormone, a potentially modifiable biological

23 Parathyroid hormone above the upper limit of normal (65

24 signature of the arrestin pathway-selective parathyroid hormone analog [d-Trp(12), Tyr(34)]bovine PT

25 growth factor-1 and high, but not low, dose parathyroid hormone and exogenous Wnt-3a.

26 albumin and inversely associated with serum parathyroid hormone and ferritin.

27 in chronic kidney disease and the effects of parathyroid hormone and FGF23 on these associations.

28 ant role for vitamin D and related hormones, parathyroid hormone and fibroblast growth factor 23 (FGF

29 splant patients significantly reduced intact parathyroid hormone and increased fibroblast growth fact

30 -dihydroxyvitamin D (1,25(OH)2D), FGF23, and parathyroid hormone and performed quantitative echocardi

31 P(i) and various hormones, including parathyroid hormone and phosphatonins, such as fibroblas

32 ts of histologic analysis, as well as intact parathyroid hormone and serum calcium values obtained 1

33 Paricalcitol decreases intact parathyroid hormone and the frequency of secondary hyper

34 alphas also inhibited internalization of the parathyroid hormone and type 2 vasopressin receptors.

35 rations <20 ng/mL who did not also have high parathyroid hormone and women with high parathyroid horm

36 luding C-terminal fragment of FGF-23, intact parathyroid hormone, and 1,25(OH)(2)D(3), were measured

37 Maternal 25(OH)D, parathyroid hormone, and 1,25-dihydroxyvitamin D [1,25(O

38 ulated by numerous factors, including BMP-2, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D3 (

39 ium, phosphorus, 25-hydroxyvitamin D, intact parathyroid hormone, and 24,25-dihydroxyvitamin D did no

40 use of monoclonal or polyclonal antibodies), parathyroid hormone, and albumin.

41 ong hormones, including 1,25(OH)2D3 (1,25D), parathyroid hormone, and fibroblast growth factor 23 (FG

42 he HDF cohort had lower beta2-microglobulin, parathyroid hormone, and high-sensitivity C-reactive pro

43 eomalacia, hypophosphatemia, increased serum parathyroid hormone, and increased levels of the phospha

44 ar, serum osteocalcin, total calcium, intact parathyroid hormone, and increased serum C telopeptide.

45 , creatinine clearance, phosphorus, calcium, parathyroid hormone, and no cortical porosity).

46 plasma levels of FGF23, calcium, phosphate, parathyroid hormone, and vitamin D metabolites.

47 ffect on basal bone resorption, it inhibited parathyroid hormone- and ovariectomy-induced OC activati

48 er levels of serum calcium, phosphorous, and parathyroid hormone; and nutritional vitamin D, cinacalc

49 terminal propeptide (PINP), osteocalcin, and parathyroid hormone as well as a transient decrease in t

50 oxyvitamin D, vitamin D-binding protein, and parathyroid hormone as well as bone mineral density (BMD

51 substantial single-pass renal extraction of parathyroid hormone at a rate that exceeds glomerular fi

52 More biochemical surveillance particularly a parathyroid hormone-based protocol, fine-tuned supplemen

53 hly expressed in osteocytes, is regulated by parathyroid hormone both in vitro and in vivo, and prote

54 nine, lower hematocrit, and increased intact parathyroid hormone but did not demonstrate any differen

55 FGF23, despite having high concentrations of parathyroid hormone, but administration of exogenous 1,2

56 evels, serum calcium homeostasis biomarkers (parathyroid hormone, calcium, and 25-hydroxyvitamin D),

57 relationships), yet within each quintile of parathyroid hormone concentration, blacks had significan

58 espectively; P=0.71) and within quintiles of parathyroid hormone concentration.

59 whether lower 25-hydroxyvitamin D and higher parathyroid hormone concentrations are associated with i

60 However, parathyroid hormone concentrations decreased in all 3 gr

61 sis did not have major effects on calcium or parathyroid hormone concentrations in either trial.

62 turic response occurred after plasma PO4 and parathyroid hormone concentrations increased.

63 Higher serum parathyroid hormone concentrations showed a significant,

64 intervals (CIs) for 25-hydroxyvitamin D and parathyroid hormone concentrations with incident hyperte

65 perparathyroidism, and might be predicted by parathyroid hormone concentrations, even in individuals

66 KO and WT mice had similar serum calcium and parathyroid hormone concentrations.

67 tein 3 but lower 1,25-dihydroxyvitamin D and parathyroid hormone concentrations.

68 The proportionate renal extraction of parathyroid hormone correlated with eGFR.

69 operative success, defined by intraoperative parathyroid hormone criteria, and complication rates wer

70 Intact parathyroid hormone decreased in paricalcitol-treated pa

71 th the use of dual-stable isotopes, 25(OH)D, parathyroid hormone, estradiol, calcitriol, and urinary

72 a common endocrine disease characterized by parathyroid hormone excess and hypercalcemia and caused

73 minal aortic calcification, serum phosphate, parathyroid hormone, FGF23, and 24-hour urinary phosphat

74 etermined the single-pass renal clearance of parathyroid hormone, fibroblast growth factor 23, vitami

75 /- 10.3 ng/mL; P < 0.0001) and a decrease in parathyroid hormone (from 21.4 +/- 10.4 to 12.9 +/- 7.1

76 splantation, persistent hyperparathyroidism (parathyroid hormone > 130 ng/L) and bone turnover marker

77 s with secondary hyperparathyroidism (intact parathyroid hormone >/=300 pg/mL).

78 Compared with parathyroid hormone <33 pg/ml, parathyroid hormone >/=65 pg/ml was associated with a si

79 th low urine output, low serum albumin, high parathyroid hormone, high ferritin, and the use of bioin

80 Intermittent Parathyroid Hormone (I-PTH) is the only FDA approved ana

81 at 1000 IU/d increases 25(OH)D and decreases parathyroid hormone in children with average vitamin D i

82 with decreased creatinine, phosphorous, and parathyroid hormone in the rats with CKD.

83 The endocrine and bone anabolic agent parathyroid hormone increased specialized proresolving m

84 Levels of parathyroid hormone increased with decreasing levels of

85 der these circumstances both agents enhanced parathyroid hormone-induced osteoblast differentiation a

86 coid receptor to potentiate vitamin D(3) and parathyroid hormone-induced osteoclastogenesis.

87 Intraoperative parathyroid hormone (IoPTH) monitoring has enabled surge

88 rmine whether to wait for the intraoperative parathyroid hormone (ioPTH) or to explore further.

89 ients with hypercalcemia and elevated intact parathyroid hormone (iPTH) concentration were eligible i

90 ium concentration is within normal range but parathyroid hormone is elevated in the absence of any ob

91 aemia caused by autonomous overproduction of parathyroid hormone, is common, especially in postmenopa

92 x, and creatinine clearance, but with intact parathyroid hormone less than 100 pg/mL, were included a

93 ltiply by 0.25; P = .15), preoperative serum parathyroid hormone level (mean [SD], 114.5 [56.8] vs 13

94 rogression were age, baseline total or whole parathyroid hormone level greater than nine times the no

95 Regarding modifiable factors, higher average parathyroid hormone level was associated with greater ri

96 walking, and higher average log-transformed parathyroid hormone level were independently associated

97 ent risk was attenuated after adjustment for parathyroid hormone level, suggesting that parathyroid h

98 sphatemia and hypomagnesemia with low plasma parathyroid hormone level.

99 Patients on HD with intact parathyroid hormone levels </=300 pg/ml receiving dialys

100 nover in patients on HD with baseline intact parathyroid hormone levels </=300 pg/ml.

101 ncreased sessional dialysis dose and lowered parathyroid hormone levels (from 51 +/- 67 to 24 +/- 37

102 ficiency at day 7 having significantly lower parathyroid hormone levels (p<0.01).

103 lerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral me

104 itamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients w

105 6-month paricalcitol supplementation reduced parathyroid hormone levels and proteinuria, attenuated b

106 Parathyroid hormone levels at 12 months decreased with a

107 Parathyroid hormone levels decreased over the study peri

108 s induced by aldosteronism in which elevated parathyroid hormone levels raise the risk of adverse car

109 baseline, median (interquartile range) serum parathyroid hormone levels significantly declined on par

110 Median intact parathyroid hormone levels were lower and severe hyperpa

111 Treatment with paricalcitol reduced parathyroid hormone levels within 4 weeks and maintained

112 mice had significantly lower serum FGF23 and parathyroid hormone levels, and higher renal 1-alpha-hyd

113 irmed by exploratory surgery, intraoperative parathyroid hormone levels, and pathologic features.

114 by increased serum 1,25-(OH)2-vitamin D3 and parathyroid hormone levels, decreased serum calcium leve

115 response or a hormonal response to decreased parathyroid hormone levels, we subjected osteocytes to a

116 ents also displayed higher plasma FGF-23 and parathyroid hormone levels.

117 l function, or preoperative serum calcium or parathyroid hormone levels.

118 ocorticoid exposure and greater decreases in parathyroid hormone levels.

119 In this study, we report that TIP39, a parathyroid hormone ligand family member that was recent

120 5 (Gdf5), the transcription factor Erg, and parathyroid hormone-like hormone (Pthlh), and selection

121 orylation and TGF-beta-induced expression of parathyroid hormone-like hormone (PTHLH), leading to ost

122 , and Ihh target genes Patched 1 (Ptch1) and parathyroid hormone-like peptide (Pthlh) were down-regul

123 Pth4, an ancient parathyroid hormone lost in eutherian mammals, reveals a

124 Compared with parathyroid hormone <33 pg/ml, parathyroid hormone >/=65

125 Impaired renal clearance of parathyroid hormone may contribute to secondary hyperpar

126 r parathyroid hormone level, suggesting that parathyroid hormone may mediate this association.

127 asive parathyroidectomy using intraoperative parathyroid hormone monitoring remains the standard appr

128 y invasive parathyroidectomy, intraoperative parathyroid hormone monitoring via a reliable protocol i

129 affect existing criteria for intraoperative parathyroid hormone monitoring.

130 olysis contribute to the anabolic actions of parathyroid hormone on the skeleton.

131 In parathyroid hormone or 1alpha,25(OH)2-vitamin D3 (D3)-st

132 strogen deficiency and sustained exposure to parathyroid hormone or RANKL.

133 nce interval (CI) 1.1-2.8], increasing serum parathyroid hormone (OR 1.1 per 10 pg/mL 95% CI 1.05-1.1

134 ccurred in serum calcium, phosphorus, intact parathyroid hormone, or C-reactive protein levels, cinac

135 not be explained by hypocalcemia, changes in parathyroid hormone, or fibroblast growth factor 23.

136 , levels of calcium, phosphorus, calcitriol, parathyroid hormone, or fibroblast growth factor-23 were

137 not explained by urine phosphate excretion, parathyroid hormone, or fibroblast growth factor-23.

138 citol treatment significantly reduced intact parathyroid hormone (P<0.001) and alkaline phosphatase (

139 etabolic pathway (e.g., 25-hydroxyvitamin D, parathyroid hormone, phosphorus) had little impact.

140 nine, free thyroxine, free triiodothyronine, parathyroid hormone, prolactin, N-terminal pro-brain nat

141 um metabolism was defined as elevated intact parathyroid hormone (PTH) (>62 pg/mL) accompanied by a v

142 Intermittent administration of a fragment of Parathyroid hormone (PTH) activates osteoblast-mediated

143 Parathyroid hormone (PTH) activates receptors on osteocy

144 Intermittent parathyroid hormone (PTH) administration increases syste

145 cium through processes that are regulated by parathyroid hormone (PTH) and 1alpha,25-dihydroxyvitamin

146 Parathyroid hormone (PTH) and calcium levels, recurrent

147 Parathyroid hormone (PTH) and FGF23 are the primary horm

148 Parathyroid hormone (PTH) and fibroblast growth factor 2

149 a/c and levels of plasma phosphate, calcium, parathyroid hormone (PTH) and fibroblast growth factor 2

150 echanisms through which Pi intake stimulates parathyroid hormone (PTH) and fibroblast growth factor-2

151 coupled receptors (GPCRs) and natively binds parathyroid hormone (PTH) and parathyroid hormone relate

152 tissue development, has two native agonists, parathyroid hormone (PTH) and PTH-related protein (PTHrP

153 Parathyroid hormone (PTH) and the sympathetic tone promo

154 The bone catabolic actions of parathyroid hormone (PTH) are seen in patients with hype

155 Continuous parathyroid hormone (PTH) blocks its own osteogenic acti

156 Previously, we have shown that intermittent parathyroid hormone (PTH) bone anabolic therapy involves

157 ic whites, but whether adding information on parathyroid hormone (PTH) can help explain the higher ca

158 3 patients receiving hemodialysis with serum parathyroid hormone (PTH) concentrations higher than 500

159 ravenous calcimimetic etelcalcetide on serum parathyroid hormone (PTH) concentrations in patients rec

160 dc73(+/-) mice also had increased mean serum parathyroid hormone (PTH) concentrations.

161 Intermittent administration of parathyroid hormone (PTH) dramatically increases bone ma

162 Parathyroid hormone (PTH) has complex effects on bone, i

163 and urine levels of minerals, and levels of parathyroid hormone (PTH) in healthy postmenopausal wome

164 ], 1,25-dihydroxyvitamin D [1,25(OH)2D], and parathyroid hormone (PTH) in maternal circulation and co

165 he PT-Dicer(-/-) mice did not increase serum parathyroid hormone (PTH) in response to acute hypocalce

166 ide (PTHrP), prevented the decrease in serum Parathyroid Hormone (PTH) induced by lactation, but ampl

167 Parathyroid hormone (PTH) induces osteoclast formation a

168 Genes related to the parathyroid hormone (PTH) influence cutaneous immune def

169 Parathyroid hormone (PTH) is a critical regulator of ske

170 Parathyroid hormone (PTH) is a primary calcium regulator

171 Parathyroid hormone (PTH) is an important regulator of o

172 Parathyroid hormone (PTH) is known for its ability to 'b

173 Parathyroid hormone (PTH) is recognized to be an importa

174 Parathyroid hormone (PTH) is the only current anabolic t

175 Parathyroid hormone (PTH) is the only Food and Drug Admi

176 yroidism is characterized by increased serum parathyroid hormone (PTH) level and parathyroid cell pro

177 ce and impact of HPT, defined as an elevated parathyroid hormone (PTH) level, after renal transplanta

178 CFR was inversely related to parathyroid hormone (PTH) levels (r=-0.3, P<0.004).

179 ibited reduced serum inorganic phosphate and parathyroid hormone (PTH) levels and decreased bone form

180 nvestigated the association between baseline parathyroid hormone (PTH) levels and major cardiovascula

181 Measuring the Parathyroid hormone (PTH) levels assists in the investig

182 l quantitative computed tomography (HRpQCT), parathyroid hormone (PTH) levels, and bone turnover mark

183 ned assessment of 25-OH-D with its regulator parathyroid hormone (PTH) may be required for optimal ev

184 ive agents 1,25(OH)(2)-vitamin D(3) (D3) and parathyroid hormone (PTH) on osteoclastogenesis.

185 otic-treated or germ-free mice, we show that parathyroid hormone (PTH) only caused bone loss in mice

186 ia, anti-KRN23 antibodies, or elevated serum parathyroid hormone (PTH) or creatinine.

187 Parathyroid hormone (PTH) orchestrates the signaling of

188 isciplinary analytical characterization of a parathyroid hormone (PTH) peptide active pharmaceutical

189 Intermittent administration of parathyroid hormone (PTH) promotes new bone formation in

190 Agonist-induced phosphorylation of the parathyroid hormone (PTH) receptor 1 (PTHR1) regulates r

191 osteoblastic cell-specific activation of the parathyroid hormone (PTH) receptor attenuates BCR-ABL1 o

192 Vitamin D and parathyroid hormone (PTH) regulate mineral metabolism an

193 alloproteinase-13 (MMP-13) transcription and parathyroid hormone (PTH) regulates HDAC4 to control MMP

194 aR) modulates renal calcium reabsorption and parathyroid hormone (PTH) secretion and is involved in t

195 ition of the abundant let-7 family increased parathyroid hormone (PTH) secretion in normal and uremic

196 , whether they had any functional effects on parathyroid hormone (PTH) secretion in parathyroid neopl

197 in D receptor agonists are known to suppress parathyroid hormone (PTH) secretion.

198 CLA treatment increased serum parathyroid hormone (PTH) significantly (p=0.0172), whil

199 Intermittent administration of parathyroid hormone (PTH) stimulates bone formation in v

200 Upon parathyroid hormone (PTH) stimulation, the PTHR internal

201 e typically on either oral bisphosphonate or parathyroid hormone (PTH) therapy.

202 absence of ascorbate and were stimulated by parathyroid hormone (PTH) to undergo rapid osteoclast fo

203 A complex feedback mechanism between parathyroid hormone (PTH), 1,25(OH)2D3 (1,25D), and fibr

204 was the primary outcome, and serum calcium, parathyroid hormone (PTH), 1,25-dihydroxyvitamin D [1,25

205 ogenesis, confluent BMSCs were cultured with parathyroid hormone (PTH), 1,25-dihydroxyvitamin D3 (1,2

206 Circulating parathyroid hormone (PTH), 25(OH)D, calcium and peripher

207 In response to parathyroid hormone (PTH), a bone anabolic hormone, LepR

208 Human parathyroid hormone (PTH), a member of class B GPCRs, bi

209 on tubular reabsorption of phosphate (TRP), parathyroid hormone (PTH), bone alkaline phosphatase (BA

210 Serum parathyroid hormone (PTH), calcium, phosphorus and alkal

211 xamined the prospective associations between parathyroid hormone (PTH), circulating 25-hydroxyvitamin

212 parathyroid chief and oxyphil cells produce parathyroid hormone (PTH), express the calcium-sensing r

213 y regulated in a highly reciprocal manner by parathyroid hormone (PTH), fibroblast growth factor 23 (

214 mber 1 (CYP27B1), whose gene is regulated by parathyroid hormone (PTH), fibroblast growth factor 23 (

215 BD) parameters including calcium, phosphate, parathyroid hormone (PTH), fibroblast growth factor 23 (

216 ercalcemic patients underwent measurement of parathyroid hormone (PTH), had documentation of hypercal

217 Teriparatide, a recombinant form of parathyroid hormone (PTH), is the only approved treatmen

218 transferrin saturation (TSAT) concentration, parathyroid hormone (PTH), IV vitamin D dose, cinacalcet

219 ata defined by their pretransplant levels of parathyroid hormone (PTH), low PTH (>65 to </=300 pg/mL;

220 ALN, parathyroid hormone (PTH), or saline (vehicle control) w

221 enes involved in signaling through Wnt, FSH, parathyroid hormone (PTH), oxytocin, and calcineurin/nuc

222 vels of fibroblast growth factor-23 (FGF23), parathyroid hormone (PTH), phosphate, and 25-hydroxyvita

223 ced bone deposition with decreased levels of parathyroid hormone (PTH), which is a key regulator of b

224 over and pronounced osteoblast resistance to parathyroid hormone (PTH), which is indicated by decreas

225 des: glucagon-like peptide-1 (GLP-1) and the parathyroid hormone (PTH), which respectively help contr

226 itory effects of TCN on lipopolysaccharide-, parathyroid hormone (PTH)-, and prostaglandin E2 (PGE2)-

227 al to Cyp27b1 that mediates unique basal and parathyroid hormone (PTH)-, fibroblast growth factor 23

228 nique role of osteal macrophages in bone and parathyroid hormone (PTH)-dependent bone anabolism using

229 urinary calcium excretion in the context of parathyroid hormone (PTH)-dependent hypercalcemia, but t

230 m MS analysis, we characterized the sites of parathyroid hormone (PTH)-induced NHERF1 phosphorylation

231 m baseline in blood and urine markers of the parathyroid hormone (PTH)-vitamin D-fibroblast growth fa

232 f preoperative serum calcium by preoperative parathyroid hormone (PTH).

233 ts in response to mechanical stimulation and parathyroid hormone (PTH).

234 oncentration >/=30 ng/mL) and decrease serum parathyroid hormone (PTH).

235 iciting concentration-dependent secretion of parathyroid hormone (PTH).

236 st growth factor 23 (FGF23) and reduction of parathyroid hormone (PTH).

237 e anabolism through direct activation of the parathyroid hormone (PTH)/PTH-related protein receptor (

238 ostasis and is tightly regulated through the parathyroid hormone (PTH)/PTHrP receptor (PTH1R) signali

239 We reveal the existence of an ancient parathyroid hormone (Pth)4 in zebrafish that was seconda

240 Parathyroid hormone (PTH, 84 residues) and PTH-related p

241 Synthetic parathyroid hormone [PTH(1-34)] has been investigated fo

242 roid hormone-related protein (PTHrP) and its parathyroid hormone/PTHrP receptor PPR.

243 The PTH1R (PTH [parathyroid hormone]/PTHrP [PTH-related protein] recepto

244 The G protein-coupled parathyroid hormone receptor (PTHR) regulates mineral-io

245 The type-1 parathyroid hormone receptor (PTHR1), which regulates ca

246 Parathyroid hormone receptor 1 (PTH1R) belongs to the se

247 The parathyroid hormone receptor 1 (PTHR1) is a member of th

248 However, parathyroid hormone receptor type 1 (PTHR), an essential

249 Together with recent work on the parathyroid hormone receptor, these data support the exi

250 The parathyroid hormone receptor-1 (PTH1R) is a class B G pr

251 We address activation of parathyroid hormone receptor-1 (PTHR1) and improve the s

252 Using an agonist of parathyroid hormone receptor-1 (PTHR1), a G protein-coup

253 tain interacting partners such as Lfc or the parathyroid hormone receptor.

254 , Ctsk deletion in osteocytes increased bone Parathyroid Hormone related Peptide (PTHrP), prevented t

255 natively binds parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP).

256 The majority of cells expressing parathyroid hormone-related peptide (PTHrP) are in the d

257 Parathyroid hormone-related peptide (PTHrP) is recognize

258 pression in chondrocytes strictly depends on parathyroid hormone-related peptide (PTHrP) signaling pa

259 r translocation of Gli2 and transcription of parathyroid hormone-related peptide (PTHrP), a key regul

260 st and prostate cancer metastasis biomarker, parathyroid hormone-related peptide (PTHrP).

261 ATDC5 chondrogenic cells is downregulated by parathyroid hormone-related peptide through transcriptio

262 targets (plasminogen activator inhibitor-1, parathyroid hormone-related peptide, connective tissue g

263 ix protein 1, a direct targeting molecule of parathyroid hormone-related peptide, negatively regulate

264 ells are regulated by autocrine signaling by parathyroid hormone-related protein (PTHrP) and its para

265 Parathyroid hormone-related protein (PTHrP) contributes

266 K14-PTHrP transgenic mice [which overexpress parathyroid hormone-related protein (PTHrP) in their dev

267 Parathyroid hormone-related protein (PTHrP) is a critica

268 Parathyroid hormone-related protein (PTHrP) is produced

269 Here we addressed the hypothesis that the parathyroid hormone-related protein (PTHrP) potentiates

270 Parathyroid hormone-related protein (PTHrP) regulates ce

271 Increased levels of parathyroid hormone-related protein (PTHrP), known to in

272 nscription factor Gli2 as a key regulator of parathyroid hormone-related protein (PTHrP), which is pr

273 egulates endochondral ossification in both a parathyroid hormone-related protein (PTHrP)-dependent an

274 ivation, increased Indian hedgehog (Ihh) and parathyroid hormone-related protein (Pthrp, also known a

275 sion data suggested that the Indian Hedgehog-parathyroid hormone-related protein signaling axis was i

276 as been made in determining the roles of the parathyroid hormone-related protein, Indian hedgehog, fi

277 or the quantification of a cancer biomarker (parathyroid hormone-related protein, PTHrP) in a real cl

278 sis in the absence of the receptor (PPR) for parathyroid hormone-related protein.

279 cancer cachexia, we show that tumour-derived parathyroid-hormone-related protein (PTHrP) has an impor

280 een the groups, patients who did not mount a parathyroid hormone response to vitamin D deficiency had

281 nthracenyl-terpyridine as a modulator of the parathyroid hormone response.

282 as phosphates, fibroblast growth factor 23, parathyroid hormone, sclerostin, or vitamin D and their

283 ices with isoproterenol, norepinephrine, and parathyroid hormone similarly increased NCC phosphorylat

284 roblast growth factor (FGF-2)-knockout mice, parathyroid hormone stimulation and myeloablative treatm

285 ndomized to receive 20 mug recombinant human parathyroid hormone (teriparatide) or placebo for 18 mon

286 Beyond hypophosphatemia and increased parathyroid hormone, the most common adverse drug reacti

287 ositively by 1,25(OH)2D3, retinoic acid, and parathyroid hormone through both intergenic and intronic

288 Osteo-active parathyroid hormone treatment abolishes infection-trigge

289 Parathyroid-hormone-type 1 receptor (PTH1R) is extensive

290 calcium, phosphate, 25-hydroxyvitamin D, and parathyroid hormone), various inflammatory markers (C-re

291 me BP, plasma and urine electrolytes, renin, parathyroid hormone, vitamin D, and response to oral glu

292 xyvitamin D was 26.3 +/- 11.2 ng/ml and mean parathyroid hormone was 41.2 +/- 17.3 pg/ml.

293 Intact parathyroid hormone was related to higher systolic and d

294 nal 25-hydroxyvitamin D [25(OH)D] and intact parathyroid hormone were measured at entry to care (mean

295 Serum 25-hydroxyvitamin D and intact parathyroid hormone were measured from previously frozen

296 Serum albumin, 25(OH)D, and intact parathyroid hormone were measured.

297 Normal serum phosphate and parathyroid hormone were observed in HMWKO mice.

298 is defined by a high concentration of intact parathyroid hormone when circulating 25-hydroxyvitamin D

299 high parathyroid hormone and women with high parathyroid hormone whose 25(OH)D concentrations were >2

300 actor 23 was, on average, lower than that of parathyroid hormone with greater variability across indi